Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
Tourmaline Bio (NASDAQ: TRML) is set to host a webinar titled 'Understanding the Genetic Validation for IL-6 Inhibition in Cardiovascular Disease' on Friday, November 1, 2024, at 9:30 AM ET. The event will feature Dr. Dipender Gill, CEO and Founder of Sequoia Genetics, a renowned expert in leveraging human genetics for drug discovery and development.
The webinar will explore recent advancements in using human genetics to inform therapeutic strategies targeting IL-6 signaling pathways. Dr. Gill, with over 250 published papers and significant contributions to Mendelian randomization research, will discuss how genetic insights are guiding new approaches for treating high-risk cardiovascular patients.
As cardiovascular disease remains a leading cause of global morbidity and mortality, this webinar aims to shed light on innovative approaches beyond traditional treatments. Interested participants can register through the Tourmaline Bio website, where a replay will also be available after the event.
Tourmaline Bio (NASDAQ: TRML) ospiterà un webinar intitolato 'Comprendere la Validazione Genetica per l'Inibizione dell'IL-6 nelle Malattie Cardiovascolari' venerdì 1 novembre 2024, alle 9:30 AM ET. L'evento vedrà la partecipazione del Dr. Dipender Gill, CEO e Fondatore di Sequoia Genetics, un esperto rinomato nell'utilizzo della genetica umana per la scoperta e lo sviluppo di farmaci.
Il webinar esplorerà i recenti progressi nell'utilizzo della genetica umana per informare le strategie terapeutiche che mirano ai percorsi di segnalazione dell'IL-6. Il Dr. Gill, con oltre 250 articoli pubblicati e significative contribuzioni alla ricerca sulla randomizzazione mendeliana, discuterà di come le intuizioni genetiche stiano guidando nuovi approcci per il trattamento di pazienti cardiovascolari ad alto rischio.
Poiché le malattie cardiovascolari rimangono una delle principali cause di morbidità e mortalità a livello globale, questo webinar si propone di mettere in luce approcci innovativi oltre ai trattamenti tradizionali. I partecipanti interessati possono registrarsi attraverso il sito web di Tourmaline Bio, dove sarà disponibile anche una registrazione dopo l'evento.
Tourmaline Bio (NASDAQ: TRML) organizará un seminario web titulado 'Comprendiendo la Validación Genética para la Inhibición de IL-6 en Enfermedades Cardiovasculares' el viernes 1 de noviembre de 2024, a las 9:30 AM ET. El evento contará con la participación del Dr. Dipender Gill, CEO y Fundador de Sequoia Genetics, un experto reconocido en el uso de la genética humana para el descubrimiento y desarrollo de fármacos.
El seminario web explorará los recientes avances en el uso de la genética humana para informar estrategias terapéuticas dirigidas a las vías de señalización de IL-6. El Dr. Gill, con más de 250 artículos publicados y contribuciones significativas a la investigación de randomización mendeliana, discutirá cómo las percepciones genéticas están guiando nuevos enfoques para tratar a pacientes cardiovasculares de alto riesgo.
Dado que las enfermedades cardiovasculares siguen siendo una de las principales causas de morbilidad y mortalidad global, este seminario web tiene como objetivo arrojar luz sobre enfoques innovadores más allá de los tratamientos tradicionales. Los participantes interesados pueden registrarse a través del sitio web de Tourmaline Bio, donde también estará disponible una repetición después del evento.
투말린 바이오 (NASDAQ: TRML)는 '심혈관 질환에서 IL-6 억제를 위한 유전적 검증 이해하기'라는 제목의 웨비나를 2024년 11월 1일 금요일 오전 9시 30분 ET에 개최할 예정입니다. 이 행사에는 약물 발견 및 개발을 위한 인간 유전자 활용의 저명한 전문가인 세콰이어 제네틱스의 CEO 및 창립자인 딥렌더 길 박사가 참석합니다.
웨비나는 IL-6 신호 전달 경로를 목표로 하는 치료 전략을 알리기 위해 인간 유전학을 활용한 최근 발전에 대해 탐구할 것입니다. 250편 이상의 학술지를 발표한 길 박사는 멘델식 무작위화 연구에 대한 중요한 기여를 해왔으며, 유전적 통찰이 고위험 심혈관 환자를 치료하기 위한 새로운 접근법을 어떻게 안내하는지 논의할 것입니다.
심혈관 질환은 여전히 전 세계적인 이환율과 사망률의 주요 원인으로 남아 있으므로, 이번 웨비나는 전통적인 치료 방법을 넘어선 혁신적인 접근 방식을 조명하는 것을 목표로 합니다. 관심 있는 참여자는 투말린 바이오 웹사이트를 통해 등록할 수 있으며, 이벤트 후에는 replay도 제공될 예정입니다.
Tourmaline Bio (NASDAQ: TRML) va organiser un webinaire intitulé 'Comprendre la validation génétique pour l'inhibition de l'IL-6 dans les maladies cardiovasculaires' le vendredi 1er novembre 2024, à 9h30 ET. L'événement mettra en vedette Dr. Dipender Gill, PDG et fondateur de Sequoia Genetics, un expert renommé dans l'utilisation de la génétique humaine pour la découverte et le développement de médicaments.
Le webinaire explorera les récentes avancées dans l'utilisation de la génétique humaine pour informer des stratégies thérapeutiques visant les voies de signalisation de l'IL-6. Le Dr Gill, avec plus de 250 articles publiés et des contributions significatives à la recherche sur la randomisation mendélienne, discutera de la façon dont les connaissances génétiques orientent de nouvelles approches pour traiter les patients cardiovasculaires à haut risque.
Alors que les maladies cardiovasculaires demeurent une cause majeure de morbidité et de mortalité dans le monde, ce webinaire vise à mettre en lumière des approches innovantes au-delà des traitements traditionnels. Les participants intéressés peuvent s'inscrire via le site web de Tourmaline Bio, où un replay sera également disponible après l'événement.
Tourmaline Bio (NASDAQ: TRML) veranstaltet ein Webinar mit dem Titel 'Verstehen der genetischen Validierung für die IL-6-Hemmung bei Herz-Kreislauf-Erkrankungen' am Freitag, den 1. November 2024, um 9:30 Uhr ET. Bei der Veranstaltung wird Dr. Dipender Gill, CEO und Gründer von Sequoia Genetics und renommierter Experte für die Nutzung menschlicher Genetik zur Arzneimittelentdeckung und -entwicklung, zu Gast sein.
Das Webinar wird aktuelle Fortschritte bei der Nutzung menschlicher Genetik zur Unterstützung therapeutischer Strategien, die auf IL-6-Signalwege abzielen, erkunden. Dr. Gill wird, basierend auf über 250 veröffentlichten Arbeiten und bedeutenden Beiträgen zur mendelschen Randomisierungsforschung, diskutieren, wie genetische Erkenntnisse neue Ansätze zur Behandlung von Hochrisikopatienten mit Herz-Kreislauf-Erkrankungen leiten.
Da Herz-Kreislauf-Erkrankungen eine der Hauptursachen für globale Morbidität und Mortalität bleiben, zielt dieses Webinar darauf ab, innovative Ansätze jenseits traditioneller Behandlungen zu beleuchten. Interessierte Teilnehmer können sich über die Website von Tourmaline Bio registrieren, wo auch eine Aufzeichnung nach der Veranstaltung verfügbar sein wird.
- None.
- None.
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a webinar, Understanding the Genetic Validation for IL-6 Inhibition in Cardiovascular Disease, featuring Dr. Dipender Gill, CEO and Founder of Sequoia Genetics. The webinar will be held on Friday, November 1, at 9:30 AM ET and will explore the latest advancements in leveraging human genetics to inform therapeutic strategies targeting IL-6 signaling pathways.
Dr. Gill, a leader in leveraging human genetic evidence to inform drug discovery and development, will share how human genetic insights are advancing IL-6 inhibition strategies and guiding new approaches for treating high-risk cardiovascular patients. With over 250 published papers and significant contributions to Mendelian randomization research, Dr. Gill is recognized as a leading voice in translating genetic data into actionable therapeutic strategies. As cardiovascular disease remains one of the leading causes of morbidity and mortality globally1, there is an increasing need for innovative approaches that go beyond traditional treatments. This webinar will explore how these advancements are reshaping the understanding of cardiovascular disease biology and opening avenues for more precise, targeted treatments.
To register for the webinar, please click here or visit the “Events and Presentations” section of the Tourmaline Bio website at https://ir.tourmalinebio.com/events-presentations/events.
A replay will be archived on the Tourmaline Bio website following the event.
About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006).
For more information about Tourmaline Bio, please visit https://www.tourmalinebio.com or follow us on LinkedIn or X.
About Sequoia Genetics
Sequoia Genetics is a private limited company that works with investors, pharma and biotech by performing research that leverages genetic data to help inform drug discovery and development.
For more information on Sequoia Genetics, please visit https://sequoiagenetics.com/
Media Contact for Tourmaline
Scient PR
Sarah Mishek
SMishek@ScientPR.com
Investor Contact for Tourmaline
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
———————————————————
1 Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, McGhie DV, Mwangi J, Pervan B, Narula J, Pineiro D, Pinto FJ. The Heart of the World. Glob Heart. 2024 Jan 25;19(1):11. doi: 10.5334/gh.1288. PMID: 38273998; PMCID: PMC10809869.
FAQ
When is Tourmaline Bio (TRML) hosting the expert webinar on IL-6 inhibition in cardiovascular disease?
Who is the featured expert in Tourmaline Bio's (TRML) upcoming webinar on cardiovascular disease?
What is the main focus of Tourmaline Bio's (TRML) webinar on November 1, 2024?
How can I register for Tourmaline Bio's (TRML) webinar on cardiovascular disease?
